全文获取类型
收费全文 | 190篇 |
免费 | 14篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 3篇 |
基础医学 | 36篇 |
口腔科学 | 2篇 |
临床医学 | 17篇 |
内科学 | 74篇 |
神经病学 | 9篇 |
特种医学 | 3篇 |
外科学 | 23篇 |
综合类 | 5篇 |
预防医学 | 8篇 |
药学 | 15篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 10篇 |
2019年 | 4篇 |
2018年 | 12篇 |
2017年 | 5篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 10篇 |
2013年 | 7篇 |
2012年 | 20篇 |
2011年 | 12篇 |
2010年 | 9篇 |
2009年 | 10篇 |
2008年 | 15篇 |
2007年 | 15篇 |
2006年 | 6篇 |
2005年 | 16篇 |
2004年 | 9篇 |
2003年 | 12篇 |
2002年 | 9篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1995年 | 1篇 |
1883年 | 1篇 |
排序方式: 共有209条查询结果,搜索用时 15 毫秒
121.
122.
Khasati N Sivaprakasam R Dunning J 《Interactive Cardiovascular and Thoracic Surgery》2004,3(1):191-194
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed is whether the figure-of-eight technique is superior to the simple wire technique for closing of the sternum? Altogether 111 papers were found in Medline of which seven presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of these papers are tabulated. We conclude that the figure-of-eight wire technique is not superior to the simple wire technique for closure of the sternum. 相似文献
123.
Suenaert P Bulteel V Lemmens L Noman M Geypens B Van Assche G Geboes K Ceuppens JL Rutgeerts P 《The American journal of gastroenterology》2002,97(8):2000-2004
OBJECTIVES: A primary defect of the tight junctions and, hence, increased intestinal epithelial permeability has been proposed as a basic pathogenic event in Crohn's disease. Challenge of the mucosal immune system by the commensal gut flora would then result in chronic inflammation. Alternatively, increased permeability could be the result of inflammation. Our aim was to study intestinal permeability in refractory Crohn's disease before and after treatment with monoclonal chimeric antibodies directed against tumor necrosis factor (TNF) to investigate whether the abnormal permeability persists after control of inflammation. MErHODS: Twenty-three patients with active Crohn's disease were evaluated before and 4 wk after a single infusion of 5 mg/kg infliximab. Intestinal permeability was studied by measurement of urinary excretion of 51Cr-EDTA after oral intake. RESULTS: The increased permeation of 51Cr-EDTA through the small intestine (1.63% interquartile range [IQR] 1.06-2.07) and the overall permeation (3.27% IQR 2.40-4.38) before therapy decreased significantly after infliximab infusion to values (1.04% IQR 0.74-1.54 and 2.42% IQR 2.03-2.80, respectively) in the range of those found in normal volunteers (1.12% IQR 0.85-1.58 and 2.28% IQR 1.88-2.86, respectively). CONCLUSION: Inhibiting the proinflammatory cytokine tumor necrosis factor dramatically reduces gut inflammation and largely restores the gut barrier in Crohn's disease. Our data confirm the central role of TNF in gut barrier modulation in inflammatory conditions in vivo. 相似文献
124.
125.
126.
Rutgeerts P Lemmens L Van Assche G Noman M Borghini-Fuhrer I Goedkoop R 《Alimentary pharmacology & therapeutics》2003,17(2):185-192
BACKGROUND: Monoclonal antibodies to the pro-inflammatory cytokine tumour necrosis factor-alpha have shown efficacy in treating Crohn's disease, but can be immunogenic. Soluble tumour necrosis factor-binding proteins are being studied as potential alternative anti-tumour necrosis factor agents in Crohn's disease. AIM: To investigate the safety and efficacy of onercept, a recombinant form of the natural human soluble p55 tumour necrosis factor receptor, in the treatment of patients with active Crohn's disease. METHODS: In a pilot study, 12 patients with active Crohn's disease were randomized to receive onercept at either 11.7 or 50 mg three times weekly for 2 weeks. Patients were followed up for 6 months after the end of treatment. RESULTS: The Crohn's disease activity index decreased rapidly during treatment in both groups. Seven responses (Crohn's disease activity index decrease of 100 points) were observed over the first 6 weeks of the study, including five remissions (Crohn's disease activity index decrease of 150 points). Improvement was sustained for 2-4 months after stopping treatment. Treatment was well tolerated. No patients developed antibodies to onercept. CONCLUSIONS: Neutralizing the activity of tumour necrosis factor-alpha with its soluble p55 receptor may be valuable in the treatment of patients with Crohn's disease. Larger placebo-controlled trials are indicated. 相似文献
127.
128.
129.
A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis 总被引:7,自引:0,他引:7
Van Assche G Dalle I Noman M Aerden I Swijsen C Asnong K Maes B Ceuppens J Geboes K Rutgeerts P 《The American journal of gastroenterology》2003,98(2):369-376
OBJECTIVES: Medical therapy of refractory ulcerative colitis (UC) is associated with long-term side effects of cyclosporine and steroids. Because cyclosporine acts by inhibiting interleukin-2 (IL-2) production, we studied the efficacy and safety of humanized anti-IL2 receptor (CD25) antibodies daclizumab for refractory UC in an open label pilot study. METHODS: Ten patients with chronically active UC received daclizumab, 1 mg/kg i.v. twice with a 4-wk interval. Clinical, endoscopic, and histological evaluation was scored at regular intervals. CD25 immunohistochemistry was followed in mucosal biopsies. The primary study endpoint was clinical improvement at wk 8. RESULTS: Nine of 10 patients completed the study. The median clinical activity score decreased from a median of 8 (95% CI = 7.2-9.2) at baseline to 3.5 (95% CI = 1.4-4.9) at wk 8 (p < 0.005). Endoscopic scores were significantly decreased at wk 8 (wk 0: 8, 95% CI = 6.3-8.5; wk 8: 5.0, 95% CI = 2.6-6.3; p < 0.01). Mucosal biopsies showed a significant decrease in CD25+ cells, and there was a trend toward lower histology scores at wk 8. Quality of life as assessed by the Inflammatory Bowel Disease Questionnaire increased after therapy (baseline: 131, 95% CI = 119-178; wk 8: 169; 95% CI = 124-216, p < 0.05). Nausea was most frequently reported as an adverse event, but always in patients that were concomitantly started on azathioprine. CONCLUSIONS: The anti-IL-2R antibody daclizumab was safe and well tolerated in acute UC. Patients experienced clinical benefit along with signs of endoscopic improvement, but further controlled trials are needed to determine the therapeutic benefit of this compound. 相似文献
130.